Bed Bath & Beyond share price
Bed Bath & Beyond, Inc. · BBBY · Consumer Discretionary · Specialty Retail · last close in our records 14 August 2026 · results updated weekly · All US stock lists
Bed Bath & Beyond share price: $4.35 at the close on 14 August 2026, the latest close in our records, −50.8% in a year.
Bed Bath & Beyond, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer.
Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business.
The price has been between phases. Over the last four quarters, results have been improving. What will decide it: the next one or two quarters of results.
What is the Bed Bath & Beyond share price?
Bed Bath & Beyond, Inc.'s share price was $4.35 at the close on 14 August 2026. That is 23.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $4 and $12, and at that close it was at the low of that range.
A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.
Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 5 weeks running.
Aug 2026: $4.35, 23.0% below its 200-day average.
- Price $4.35
- 50-day avg $5.41
- 200-day avg $5.65
| Week | Price | 50-day avg | 200-day avg |
|---|---|---|---|
| 11 Jul 2025 | $7.78 | – | – |
| 18 Jul 2025 | $8.85 | – | – |
| 25 Jul 2025 | $10.09 | – | – |
| 1 Aug 2025 | $8.16 | – | – |
| 8 Aug 2025 | $7.93 | – | – |
| 15 Aug 2025 | $8.85 | – | – |
| 22 Aug 2025 | $9.70 | – | – |
| 29 Aug 2025 | $9.01 | – | – |
| 5 Sep 2025 | $9.88 | – | – |
| 12 Sep 2025 | $10.39 | – | – |
| 19 Sep 2025 | $9.52 | $9.26 | – |
| 26 Sep 2025 | $9.40 | $9.42 | – |
| 3 Oct 2025 | $12.02 | $9.43 | – |
| 10 Oct 2025 | $8.76 | $9.53 | – |
| 17 Oct 2025 | $7.87 | $9.54 | – |
| 24 Oct 2025 | $8.57 | $9.50 | – |
| 31 Oct 2025 | $7.71 | $9.40 | – |
| 7 Nov 2025 | $6.99 | $9.18 | – |
| 14 Nov 2025 | $6.03 | $8.96 | – |
| 21 Nov 2025 | $5.56 | $8.47 | – |
| 28 Nov 2025 | $6.02 | $8.14 | – |
| 5 Dec 2025 | $6.32 | $7.85 | – |
| 12 Dec 2025 | $6.33 | $7.47 | – |
| 19 Dec 2025 | $6.02 | $6.96 | – |
| 26 Dec 2025 | $5.65 | $6.72 | – |
| 2 Jan 2026 | $5.91 | $6.51 | – |
| 9 Jan 2026 | $6.85 | $6.31 | – |
| 16 Jan 2026 | $7.26 | $6.23 | – |
| 23 Jan 2026 | $6.87 | $6.23 | – |
| 30 Jan 2026 | $5.91 | $6.23 | – |
| 6 Feb 2026 | $5.47 | $6.23 | – |
| 13 Feb 2026 | $4.99 | $6.17 | – |
| 20 Feb 2026 | $5.23 | $6.06 | – |
| 27 Feb 2026 | $5.33 | $5.98 | – |
| 6 Mar 2026 | $5.01 | $5.88 | – |
| 13 Mar 2026 | $4.90 | $5.81 | – |
| 20 Mar 2026 | $4.67 | $5.69 | – |
| 27 Mar 2026 | $4.37 | $5.48 | – |
| 2 Apr 2026 | $4.62 | $5.28 | – |
| 10 Apr 2026 | $4.69 | $5.06 | – |
| 17 Apr 2026 | $5.74 | $4.98 | – |
| 24 Apr 2026 | $5.61 | $5.03 | $7.15 |
| 1 May 2026 | $5.44 | $5.03 | $7.09 |
| 8 May 2026 | $5.30 | $5.01 | $6.97 |
| 15 May 2026 | $4.57 | $4.96 | $6.84 |
| 22 May 2026 | $5.60 | $4.99 | $6.76 |
| 29 May 2026 | $6.13 | $5.10 | $6.71 |
| 5 Jun 2026 | $5.84 | $5.24 | $6.64 |
| 12 Jun 2026 | $5.88 | $5.37 | $6.55 |
| 18 Jun 2026 | $5.93 | $5.47 | $6.49 |
| 26 Jun 2026 | $6.29 | $5.62 | $6.40 |
| 2 Jul 2026 | $5.83 | $5.64 | $6.31 |
| 10 Jul 2026 | $5.24 | $5.64 | $6.21 |
| 17 Jul 2026 | $5.03 | $5.64 | $6.11 |
| 24 Jul 2026 | $4.96 | $5.64 | $5.96 |
| 31 Jul 2026 | $5.05 | $5.69 | $5.84 |
| 7 Aug 2026 | $4.64 | $5.60 | $5.75 |
| 14 Aug 2026 | $4.35 | $5.41 | $5.65 |
Week by week since 2025: did it beat the S&P 500 over the past 13 weeks?
Ahead in 8 of 45 weeks
| Week | 13-week return vs S&P 500 |
|---|---|
| 11 Jul 2025 | no S&P 500 reading |
| 18 Jul 2025 | no S&P 500 reading |
| 25 Jul 2025 | no S&P 500 reading |
| 1 Aug 2025 | no S&P 500 reading |
| 8 Aug 2025 | no S&P 500 reading |
| 15 Aug 2025 | no S&P 500 reading |
| 22 Aug 2025 | no S&P 500 reading |
| 29 Aug 2025 | no S&P 500 reading |
| 5 Sep 2025 | no S&P 500 reading |
| 12 Sep 2025 | no S&P 500 reading |
| 19 Sep 2025 | no S&P 500 reading |
| 26 Sep 2025 | no S&P 500 reading |
| 3 Oct 2025 | no S&P 500 reading |
| 10 Oct 2025 | +7.9% |
| 17 Oct 2025 | −16.9% |
| 24 Oct 2025 | −21.4% |
| 31 Oct 2025 | −15.2% |
| 7 Nov 2025 | −17.2% |
| 14 Nov 2025 | −36.3% |
| 21 Nov 2025 | −44.8% |
| 28 Nov 2025 | −39.1% |
| 5 Dec 2025 | −42.0% |
| 12 Dec 2025 | −42.8% |
| 19 Dec 2025 | −39.3% |
| 26 Dec 2025 | −44.2% |
| 2 Jan 2026 | −52.9% |
| 9 Jan 2026 | −28.1% |
| 16 Jan 2026 | −11.9% |
| 23 Jan 2026 | −21.6% |
| 30 Jan 2026 | −24.8% |
| 6 Feb 2026 | −24.7% |
| 13 Feb 2026 | −18.7% |
| 20 Feb 2026 | −10.5% |
| 27 Feb 2026 | −11.8% |
| 6 Mar 2026 | −18.8% |
| 13 Mar 2026 | −19.7% |
| 20 Mar 2026 | −17.7% |
| 27 Mar 2026 | −14.5% |
| 2 Apr 2026 | −17.8% |
| 10 Apr 2026 | −29.4% |
| 17 Apr 2026 | −23.6% |
| 24 Apr 2026 | −21.9% |
| 1 May 2026 | −12.1% |
| 8 May 2026 | −9.9% |
| 15 May 2026 | −16.8% |
| 22 May 2026 | −1.1% |
| 29 May 2026 | +4.7% |
| 5 Jun 2026 | +6.9% |
| 12 Jun 2026 | +8.0% |
| 18 Jun 2026 | +11.8% |
| 26 Jun 2026 | +29.0% |
| 2 Jul 2026 | +12.6% |
| 10 Jul 2026 | +0.6% |
| 17 Jul 2026 | −17.0% |
| 24 Jul 2026 | −15.1% |
| 31 Jul 2026 | −10.8% |
| 7 Aug 2026 | −17.3% |
| 14 Aug 2026 | −9.8% |
Over the last 1 year the share price moved −44% while the S&P 500 moved +24%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 10 July 2026. The chart above shows the 13-week comparison for every week.
This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.
What dividend does Bed Bath & Beyond pay?
Bed Bath & Beyond, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.
Which stock lists is Bed Bath & Beyond on?
Bed Bath & Beyond is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.
Is Bed Bath & Beyond profitable?
Bed Bath & Beyond, Inc. posted a net loss of $16.4 M in the Mar 2026 quarter. The full FY25 year was a loss of $84.6 M. That loss is 6.6% of the quarter's revenue. The same quarter a year earlier lost $39.9 M. 12 of the last 12 reported quarters were loss-making.
Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.
FY25 profit −$84.6 M
- Net profit −$84.6 M
| Quarter | Net profit |
|---|---|
| FY21 | $561 M |
| FY22 | −$35.2 M |
| FY23 | −$308 M |
| FY24 | −$259 M |
| FY25 | −$84.6 M |
Growth on a year earlier
- Growth on a year earlier −106.3%
| Quarter | Growth on a year earlier |
|---|---|
| FY21 | – |
| FY22 | −106.3% |
| FY23 | – |
| FY24 | – |
| FY25 | – |
Mar 2026: −$16.4 M
- Net profit (quarterly) −$16.4 M
| Quarter | Net profit (quarterly) |
|---|---|
| Jun 2023 | −$73.5 M |
| Sep 2023 | −$63.0 M |
| Dec 2023 | −$161 M |
| Mar 2024 | −$73.9 M |
| Jun 2024 | −$42.6 M |
| Sep 2024 | −$61.0 M |
| Dec 2024 | −$81.3 M |
| Mar 2025 | −$39.9 M |
| Jun 2025 | −$19.3 M |
| Sep 2025 | −$4.5 M |
| Dec 2025 | −$20.9 M |
| Mar 2026 | −$16.4 M |
Growth on a year earlier
- Growth on a year earlier −1,128.3%
| Quarter | Growth on a year earlier |
|---|---|
| Jun 2023 | −1,128.3% |
| Sep 2023 | – |
| Dec 2023 | – |
| Mar 2024 | – |
| Jun 2024 | – |
| Sep 2024 | – |
| Dec 2024 | – |
| Mar 2025 | – |
| Jun 2025 | – |
| Sep 2025 | – |
| Dec 2025 | – |
| Mar 2026 | – |
How much revenue does Bed Bath & Beyond make, and is it growing?
Bed Bath & Beyond, Inc. reported $248 M of revenue in the Mar 2026 quarter, +6.9% on the same quarter a year earlier. Over 4 years it has grown −21.5% a year on average. The last full year, FY25, came in at $1.0 B. The last four reported quarters add to $1.1 B.
Revenue is everything the company billed its customers in the period.
FY25 revenue was $1.0 B, −25.1% on the year before.
FY25 revenue $1.0 B (−25.1% on the year before), −21.5% a year over 4 years
- Revenue $1.0 B
| Quarter | Revenue |
|---|---|
| FY21 | $2.8 B |
| FY22 | $1.9 B |
| FY23 | $1.6 B |
| FY24 | $1.4 B |
| FY25 | $1.0 B |
Growth on a year earlier
- Growth on a year earlier −25.1%
| Quarter | Growth on a year earlier |
|---|---|
| FY21 | – |
| FY22 | −30% |
| FY23 | −19.1% |
| FY24 | −10.6% |
| FY25 | −25.1% |
Mar 2026: $248 M (+6.9% on a year earlier)
- Revenue (quarterly) $248 M
| Quarter | Revenue (quarterly) |
|---|---|
| Jun 2023 | $422 M |
| Sep 2023 | $373 M |
| Dec 2023 | $384 M |
| Mar 2024 | $382 M |
| Jun 2024 | $398 M |
| Sep 2024 | $311 M |
| Dec 2024 | $303 M |
| Mar 2025 | $232 M |
| Jun 2025 | $282 M |
| Sep 2025 | $257 M |
| Dec 2025 | $273 M |
| Mar 2026 | $248 M |
Growth on a year earlier
- Growth on a year earlier 6.9%
| Quarter | Growth on a year earlier |
|---|---|
| Jun 2023 | −20.1% |
| Sep 2023 | −18.9% |
| Dec 2023 | −5% |
| Mar 2024 | 0.3% |
| Jun 2024 | −5.7% |
| Sep 2024 | −16.6% |
| Dec 2024 | −21.1% |
| Mar 2025 | −39.4% |
| Jun 2025 | −29.1% |
| Sep 2025 | −17.4% |
| Dec 2025 | −9.8% |
| Mar 2026 | 6.9% |
Recent pace: the last four quarters grew −12.3% on average, against −21.5% a year over the longer run, so this year is growing faster than its own long-run rate.
Is growth speeding up? Revenue over the last 12 months grew −14.8%, against −17.6% a year over the last 8 quarters (stabilising).
How much of every $100 of sales does Bed Bath & Beyond keep?
Bed Bath & Beyond, Inc.'s operating margin was −7.3% in the Mar 2026 quarter, 2.7 percentage points higher than the same quarter a year ago. Across 5 years it has been between −13.2% and 4.0%. The latest quarter is within that range.
Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.
Why the margin moved: operating margin changed +2.7 percentage points on the year while gross margin changed −1.2 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.
FY25: −5.9%, within a range of −13.2% to 4.0% over 5 years
- Operating margin −5.9%
| Quarter | Operating margin |
|---|---|
| FY21 | 4% |
| FY22 | 1.4% |
| FY23 | −9.2% |
| FY24 | −13.2% |
| FY25 | −5.9% |
Change on the year before (points)
- Change on the year before (points) +7.3 pts
| Quarter | Change on the year before (points) |
|---|---|
| FY21 | – |
| FY22 | −2.6 pts |
| FY23 | −10.6 pts |
| FY24 | −4.0 pts |
| FY25 | +7.3 pts |
Mar 2026: operating margin −7.3% (+2.7 points on a year earlier)
- Operating margin −7.3%
| Quarter | Operating margin |
|---|---|
| Jun 2023 | −1% |
| Sep 2023 | −11% |
| Dec 2023 | −16.8% |
| Mar 2024 | −15% |
| Jun 2024 | −11.8% |
| Sep 2024 | −14.5% |
| Dec 2024 | −14.7% |
| Mar 2025 | −10% |
| Jun 2025 | −6.3% |
| Sep 2025 | −4.8% |
| Dec 2025 | −4.8% |
| Mar 2026 | −7.3% |
Change on a year earlier (points)
- Change on a year earlier (points) +2.7 pts
| Quarter | Change on a year earlier (points) |
|---|---|
| Jun 2023 | −3.2 pts |
| Sep 2023 | −12.2 pts |
| Dec 2023 | −2.3 pts |
| Mar 2024 | −12.8 pts |
| Jun 2024 | −10.8 pts |
| Sep 2024 | −3.5 pts |
| Dec 2024 | +2.1 pts |
| Mar 2025 | +5.0 pts |
| Jun 2025 | +5.5 pts |
| Sep 2025 | +9.7 pts |
| Dec 2025 | +9.9 pts |
| Mar 2026 | +2.7 pts |
Is Bed Bath & Beyond's profit turning into cash?
Bed Bath & Beyond, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $56.7 M of cash, against −$84.6 M of profit. After $7.4 M of spending on assets, free cash was −$64.1 M: it spent more than its operations brought in.
The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.
Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.
FY25: operating cash −$56.7 M against profit −$84.6 M
- Operating cash −$56.7 M
- Net profit −$84.6 M
- Free cash −$64.1 M
| Quarter | Operating cash | Net profit | Free cash |
|---|---|---|---|
| FY21 | $80.9 M | $561 M | $67.3 M |
| FY22 | −$12.5 M | −$35.2 M | −$27.4 M |
| FY23 | −$18.6 M | −$308 M | −$37.8 M |
| FY24 | −$174 M | −$259 M | −$189 M |
| FY25 | −$56.7 M | −$84.6 M | −$64.1 M |
Mar 2026: operating cash −$11.8 M
- Operating cash (quarterly) −$11.8 M
| Quarter | Operating cash (quarterly) |
|---|---|
| Jun 2023 | −$1.2 M |
| Sep 2023 | −$9.6 M |
| Dec 2023 | −$27.7 M |
| Mar 2024 | −$34.6 M |
| Jun 2024 | −$75.9 M |
| Sep 2024 | −$42.1 M |
| Dec 2024 | −$21.7 M |
| Mar 2025 | −$50.9 M |
| Jun 2025 | $15.8 M |
| Sep 2025 | −$15.1 M |
| Dec 2025 | −$6.5 M |
| Mar 2026 | −$11.8 M |
What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.
Where does Bed Bath & Beyond's cash go?
Bed Bath & Beyond, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $40.9 M on assets over the last 3 years. Averaged over those years that is 1.3% of FY25 revenue a year.
Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.
Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.
Spending on assets: $40.9 M over the last 3 years.
FY25: capex $7.4 M, down from the year before
- Capex $7.4 M
| Quarter | Capex |
|---|---|
| FY21 | $13.6 M |
| FY22 | $14.9 M |
| FY23 | $19.2 M |
| FY24 | $14.3 M |
| FY25 | $7.4 M |
Mar 2026: capex $1.0 M in the quarter
- Capex (quarterly) $1.0 M
| Quarter | Capex (quarterly) |
|---|---|
| Jun 2023 | $6.8 M |
| Sep 2023 | $4.5 M |
| Dec 2023 | $2.6 M |
| Mar 2024 | $3.4 M |
| Jun 2024 | $4.5 M |
| Sep 2024 | $3.4 M |
| Dec 2024 | $3.0 M |
| Mar 2025 | $1.2 M |
| Jun 2025 | $1.8 M |
| Sep 2025 | $2.3 M |
| Dec 2025 | $2.2 M |
| Mar 2026 | $1.0 M |
Free cash
- Free cash −$12.8 M
| Quarter | Free cash |
|---|---|
| Jun 2023 | −$8.0 M |
| Sep 2023 | −$14.1 M |
| Dec 2023 | −$30.4 M |
| Mar 2024 | −$38.0 M |
| Jun 2024 | −$80.4 M |
| Sep 2024 | −$45.5 M |
| Dec 2024 | −$24.7 M |
| Mar 2025 | −$52.1 M |
| Jun 2025 | $14.0 M |
| Sep 2025 | −$17.4 M |
| Dec 2025 | −$8.6 M |
| Mar 2026 | −$12.8 M |
In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it.
What is Bed Bath & Beyond's P/E ratio, and how does it compare with its own history?
Bed Bath & Beyond, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Bed Bath & Beyond, Inc. at 0.4× its FY25 revenue of $1.0 B. The P/E comes back here once profit turns positive.
P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.
PEG 1.61 at the Mar 2026 quarter end: above 1.0, so the P/E is bigger than the earnings growth rate
- PEG 1.61×
- PEG = 1.0 1.00×
| Quarter | PEG | PEG = 1.0 |
|---|---|---|
| Sep 2021 | 1.61× | 1.00× |
| Dec 2021 | 1.61× | 1.00× |
| Mar 2022 | 1.61× | 1.00× |
| Jun 2022 | 1.61× | 1.00× |
| Sep 2022 | 1.61× | 1.00× |
| Dec 2022 | 1.61× | 1.00× |
| Mar 2023 | 1.61× | 1.00× |
| Jun 2023 | 1.61× | 1.00× |
| Sep 2023 | 1.61× | 1.00× |
| Dec 2023 | 1.61× | 1.00× |
| Mar 2024 | 1.61× | 1.00× |
| Jun 2024 | 1.61× | 1.00× |
| Sep 2024 | 1.61× | 1.00× |
| Dec 2024 | 1.61× | 1.00× |
| Mar 2025 | 1.61× | 1.00× |
| Jun 2025 | 1.61× | 1.00× |
| Sep 2025 | 1.61× | 1.00× |
| Dec 2025 | 1.61× | 1.00× |
| Mar 2026 | 1.61× | 1.00× |
Is the Bed Bath & Beyond business getting better or worse?
Bed Bath & Beyond, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps.
Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.
Growth year by year: revenue −25.1% in FY25
- Revenue growth −25.1%
| Quarter | Revenue growth |
|---|---|
| FY21 | – |
| FY22 | −30% |
| FY23 | −19.1% |
| FY24 | −10.6% |
| FY25 | −25.1% |
Profit growth, EPS growth
- Profit growth −106.3%
- EPS growth −110.2%
| Quarter | Profit growth | EPS growth |
|---|---|---|
| FY21 | – | – |
| FY22 | −106.3% | −110.2% |
| FY23 | – | – |
| FY24 | – | – |
| FY25 | – | – |
Three growth lines over twelve quarters: revenue stabilising
- Revenue −14.8%
| Quarter | Revenue |
|---|---|
| Jun 2023 | −29.5% |
| Sep 2023 | −26% |
| Dec 2023 | −19.1% |
| Mar 2024 | −12% |
| Jun 2024 | −7.8% |
| Sep 2024 | −6.7% |
| Dec 2024 | −10.6% |
| Mar 2025 | −20.3% |
| Jun 2025 | −26.6% |
| Sep 2025 | −27.2% |
| Dec 2025 | −25.1% |
| Mar 2026 | −14.8% |
Profit, EPS
- Profit −300%
- EPS −300%
| Quarter | Profit | EPS |
|---|---|---|
| Jun 2023 | −194.7% | −283.5% |
| Sep 2023 | −300% | −300% |
| Dec 2023 | – | – |
| Mar 2024 | – | – |
| Jun 2024 | – | – |
| Sep 2024 | – | – |
| Dec 2024 | – | – |
| Mar 2025 | – | – |
| Jun 2025 | – | – |
| Sep 2025 | – | – |
| Dec 2025 | – | – |
| Mar 2026 | – | – |
ROCE: the return line, worked out each quarter
- ROCE −33.2%
| Quarter | ROCE |
|---|---|
| Jun 2023 | −9.6% |
| Sep 2023 | −17.5% |
| Dec 2023 | – |
| Mar 2024 | – |
| Jun 2024 | – |
| Sep 2024 | – |
| Dec 2024 | −67% |
| Mar 2025 | −65.5% |
| Jun 2025 | −60% |
| Sep 2025 | −43.1% |
| Dec 2025 | −32.5% |
| Mar 2026 | −33.2% |
Why it matters: with too little history, we say so rather than guess a direction.
There are fewer than eight usable quarters, so this page does not guess a direction from so little history.
Compound annual growth rate (%)
Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.
| Measure | 1yr | 3yr | 5yr | 10yr |
|---|---|---|---|---|
| Revenue | −25.1% | −18.5% | — | — |
| Stock price | −50.8% | — | — | — |
How much does Bed Bath & Beyond earn on its capital?
Bed Bath & Beyond, Inc. earned a ROE of −39% in FY25. That is up from a low of −159% in FY24. Its return on capital used (ROIC) is 55.6 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.
Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.
It comes from a −8.1% net margin and 2.46× asset turnover (sales divided by assets).
Why the return is what it is (FY25): a −8.1% net margin × 2.46× asset turnover × 1.95× leverage (assets divided by equity) ≈ −38.9% on equity. The margin does its share; borrowing is a big part of it.
The key test, return on capital used minus the cost of capital: −40.7% − 14.9% = −55.6 percentage points. The 14.9% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.
The −40.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −262.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.
FY25: ROE −39%, the climb back from FY24's −159%
- ROE −38.8%
- ROIC (annual) −262.5%
- Cost of capital 14.9%
| Quarter | ROE | ROIC (annual) | Cost of capital |
|---|---|---|---|
| FY21 | 1,038.6% | 590.7% | 14.9% |
| FY22 | −39.3% | 67.1% | 14.9% |
| FY23 | −85.7% | −366.9% | 14.9% |
| FY24 | −159% | −531.6% | 14.9% |
| FY25 | −38.8% | −262.5% | 14.9% |
Mar 2026: ROIC −220.7% (last 12 months) against a 14.9% cost of capital
- ROIC (12 months) −220.7%
- ROE (12 months) −32.9%
- Cost of capital 14.9%
| Quarter | ROIC (12 months) | ROE (12 months) | Cost of capital |
|---|---|---|---|
| Jun 2023 | −39.7% | −39.9% | 14.9% |
| Sep 2023 | −54.9% | −45.2% | 14.9% |
| Dec 2023 | −63.3% | −95.4% | 14.9% |
| Mar 2024 | −181.9% | −109.8% | 14.9% |
| Jun 2024 | −273.6% | −108.6% | 14.9% |
| Sep 2024 | −333.2% | −115.1% | 14.9% |
| Dec 2024 | −423.6% | −74.4% | 14.9% |
| Mar 2025 | −409% | −77% | 14.9% |
| Jun 2025 | −400.5% | −76.8% | 14.9% |
| Sep 2025 | −389.4% | −62% | 14.9% |
| Dec 2025 | −291.5% | −41.9% | 14.9% |
| Mar 2026 | −220.7% | −32.9% | 14.9% |
Does Bed Bath & Beyond have too much debt?
Bed Bath & Beyond, Inc. has total debt of $21.9 M against shareholder equity of $202 M as of Mar 2026, so its debt is 0.11× its equity, which is very little. Year by year, that ratio went from 0.25 in FY21 to 0.10 in FY25. So the returns on this page come from the business, not from borrowed money.
Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.
FY25: debt $22.1 M, 0.10× equity
- Total debt $22.1 M
| Quarter | Total debt |
|---|---|
| FY21 | $13.2 M |
| FY22 | $7.8 M |
| FY23 | $3.8 M |
| FY24 | $32.7 M |
| FY25 | $22.1 M |
Debt-to-equity
- Debt-to-equity 0.10×
| Quarter | Debt-to-equity |
|---|---|
| FY21 | 0.25× |
| FY22 | 0.09× |
| FY23 | 0.01× |
| FY24 | 0.20× |
| FY25 | 0.10× |
Mar 2026: debt $21.9 M, debt-to-equity 0.11
- Total debt (quarterly) $21.9 M
| Quarter | Total debt (quarterly) |
|---|---|
| Jun 2023 | $39.6 M |
| Sep 2023 | $38.9 M |
| Dec 2023 | $3.8 M |
| Mar 2024 | $3.0 M |
| Jun 2024 | $3.1 M |
| Sep 2024 | $2.2 M |
| Dec 2024 | $32.7 M |
| Mar 2025 | $32.0 M |
| Jun 2025 | $25.4 M |
| Sep 2025 | $24.8 M |
| Dec 2025 | $22.1 M |
| Mar 2026 | $21.9 M |
Debt-to-equity
- Debt-to-equity 0.11×
| Quarter | Debt-to-equity |
|---|---|
| Jun 2023 | 0.07× |
| Sep 2023 | 0.08× |
| Dec 2023 | 0.01× |
| Mar 2024 | 0.01× |
| Jun 2024 | 0.01× |
| Sep 2024 | 0.01× |
| Dec 2024 | 0.20× |
| Mar 2025 | 0.22× |
| Jun 2025 | 0.19× |
| Sep 2025 | 0.12× |
| Dec 2025 | 0.10× |
| Mar 2026 | 0.11× |
What is the Bed Bath & Beyond shareholding pattern?
We have no ownership or short-position figures for Bed Bath & Beyond, Inc., so this section says so rather than fill the gap. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.
There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.
How far is Bed Bath & Beyond from balance-sheet trouble?
For Bed Bath & Beyond, Inc., the Z-score is −0.06. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.
The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.
Why it matters: a Z-score of −0.06 is inside the danger zone, so the balance sheet is a real risk.
How does Bed Bath & Beyond rank in its industry?
38.8 out of 100, rank 28 of 28 in Specialty Retail, with 31% of the evidence available. It is provisional, so it is ranked below companies with full evidence.
Bed Bath & Beyond, Inc. scores 38.8 out of 100 against the 28 companies it is compared with in Specialty Retail, ranking 28. Some evidence is missing, so the score is pulled toward the middle on purpose.
The three scored parts add up to the total exactly: 20.1 + 7.9 + 10.8 = 38.8 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here.
What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.
Which companies is Bed Bath & Beyond compared with?
Bed Bath & Beyond ranks 28 of 28 Specialty Retail companies on the 4-Factor Sector Score, with 38.8 out of 100.
- 1Five Below, Inc.FIVE · losing its lead · Most evidence points up · 85% evidence73.1out of 100
How the score adds up
Growth & earnings 32.1/35 · Revenue 25.5% · Profit 100% · Operating margin change 3.8 points · 95% evidenceCapital efficiency 15.1/25 · ROCE 14.5% · Operating margin 8.9% · 76% evidenceValuation 13.5/20 · P/E 19.4× · PEG 0.72 · 65% evidenceRelative strength 12.4/20 · Lead over its industry 5.8% · Lead over S&P 500 11.9% · 1 year 65.5% · 100% evidence · 10 of 12 weeks aheadExact sum: 32.1 + 15.1 + 13.5 + 12.4 = 73.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 2Best Buy Co., Inc.BBY · leader · Most evidence points up · 85% evidence70.4out of 100
How the score adds up
Growth & earnings 20.0/35 · Revenue 1.4% · Profit 63.5% · Operating margin change 0 points · 95% evidenceCapital efficiency 17.2/25 · ROCE 25.4% · Operating margin 3.9% · 76% evidenceValuation 15.6/20 · P/E 14.3× · PEG 0.35 · 65% evidenceRelative strength 17.6/20 · Lead over its industry 19.1% · Lead over S&P 500 26.3% · 1 year 28.3% · 100% evidence · 10 of 12 weeks aheadExact sum: 20 + 17.2 + 15.6 + 17.6 = 70.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 3Academy Sports and Outdoors, Inc.ASO · breaking out · Most evidence points up · 85% evidence69.5out of 100
How the score adds up
Growth & earnings 21.8/35 · Revenue 3.7% · Profit 7% · Operating margin change 4.2 points · 95% evidenceCapital efficiency 15.2/25 · ROCE 13.3% · Operating margin 15% · 76% evidenceValuation 14.9/20 · P/E 7.4× · PEG 0.6 · 65% evidenceRelative strength 17.6/20 · Lead over its industry 13.8% · Lead over S&P 500 19.8% · 1 year 47.9% · 100% evidence · 6 of 12 weeks aheadExact sum: 21.8 + 15.2 + 14.9 + 17.6 = 69.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 4Bath & Body Works, Inc.BBWI · turning · Evidence leans up · 85% evidence60.9out of 100
How the score adds up
Growth & earnings 10.4/35 · Revenue -2.2% · Profit 7.3% · Operating margin change -1.5 points · 95% evidenceCapital efficiency 18.9/25 · ROCE 31.1% · Operating margin 9.6% · 76% evidenceValuation 15.9/20 · P/E 5.2× · PEG 0.36 · 65% evidenceRelative strength 15.7/20 · Lead over its industry 4.8% · Lead over S&P 500 10.2% · 1 year 2.7% · 100% evidence · 4 of 12 weeks aheadExact sum: 10.4 + 18.9 + 15.9 + 15.7 = 60.9 · What this means: Relative strength against the index is 10.2%, and revenue and profit growth are weak. - 5Murphy USA Inc.MUSA · quiet · Evidence leans up · 81% evidence60.6out of 100
How the score adds up
Growth & earnings 24.0/35 · Revenue 11.3% · Profit 25.7% · Operating margin change -0.1 points · 83% evidenceCapital efficiency 16.8/25 · ROCE 23.5% · Operating margin 4.9% · 76% evidenceValuation 14.8/20 · P/E 16.1× · PEG 0.45 · 65% evidenceRelative strength 5.0/20 · Lead over its industry -9.9% · Lead over S&P 500 -4.4% · 1 year 38.1% · 100% evidence · 0 of 12 weeks aheadExact sum: 24 + 16.8 + 14.8 + 5 = 60.6 · What this means: Earnings are strong; relative strength in its sector is -9.9% and the one-year return is 38.1%. - 6GameStop Corp.GME · breaking out · Evidence leans up · 75% evidence56.9out of 100
How the score adds up
Growth & earnings 23.7/35 · Revenue -7.7% · Profit 100% · Operating margin change 13.4 points · 95% evidenceCapital efficiency 9.6/25 · ROCE 4.7% · Operating margin 20% · 76% evidenceValuation 10.7/20 · P/E 10.9× · PEG — · 15% evidenceRelative strength 12.9/20 · Lead over its industry -0.9% · Lead over S&P 500 4.6% · 1 year 16.9% · 100% evidence · 5 of 12 weeks aheadExact sum: 23.7 + 9.6 + 10.7 + 12.9 = 56.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 7Ulta Beauty, Inc.ULTA · breaking out · Evidence leans up · 85% evidence56.5out of 100
How the score adds up
Growth & earnings 16.7/35 · Revenue 11.2% · Profit 0.8% · Operating margin change 0.1 points · 95% evidenceCapital efficiency 19.7/25 · ROCE 34.5% · Operating margin 12.5% · 76% evidenceValuation 5.7/20 · P/E 18.2× · PEG 3.52 · 65% evidenceRelative strength 14.4/20 · Lead over its industry 4.5% · Lead over S&P 500 9.9% · 1 year 27.6% · 100% evidence · 10 of 12 weeks aheadExact sum: 16.7 + 19.7 + 5.7 + 14.4 = 56.5 · What this means: Relative strength against the index is 9.9%, and revenue and profit growth are weak. - 8Sally Beauty Holdings, Inc.SBH · leader · Evidence leans up · 81% evidence55.2out of 100
How the score adds up
Growth & earnings 14.2/35 · Revenue 1.1% · Profit -0.5% · Operating margin change 0.8 points · 83% evidenceCapital efficiency 13.6/25 · ROCE 12.5% · Operating margin 9.3% · 76% evidenceValuation 11.9/20 · P/E 7× · PEG 1.28 · 65% evidenceRelative strength 15.5/20 · Lead over its industry 12.6% · Lead over S&P 500 18.9% · 1 year 37.3% · 100% evidence · 11 of 12 weeks aheadExact sum: 14.2 + 13.6 + 11.9 + 15.5 = 55.2 · What this means: Relative strength against the index is 18.9%, and revenue and profit growth are weak. - 9Williams-Sonoma, Inc.WSM · breaking out · Evidence leans up · 85% evidence54.9out of 100
How the score adds up
Growth & earnings 13.2/35 · Revenue 2.2% · Profit 4.6% · Operating margin change -0.6 points · 95% evidenceCapital efficiency 20.7/25 · ROCE 39.6% · Operating margin 17.3% · 76% evidenceValuation 6.6/20 · P/E 22.8× · PEG 2.67 · 65% evidenceRelative strength 14.4/20 · Lead over its industry 14% · Lead over S&P 500 20.5% · 1 year 37% · 100% evidence · 8 of 12 weeks aheadExact sum: 13.2 + 20.7 + 6.6 + 14.4 = 54.9 · What this means: Relative strength against the index is 20.5%, and revenue and profit growth are weak. - 10Casey's General Stores, Inc.CASY · quiet · Evidence leans up · 85% evidence52.8out of 100
How the score adds up
Growth & earnings 25.2/35 · Revenue 13.8% · Profit 33% · Operating margin change -0.2 points · 95% evidenceCapital efficiency 14.0/25 · ROCE 14.3% · Operating margin 6.5% · 76% evidenceValuation 10.2/20 · P/E 41.7× · PEG 1.25 · 65% evidenceRelative strength 3.4/20 · Lead over its industry -15.3% · Lead over S&P 500 -10.4% · 1 year 26.5% · 100% evidence · 0 of 12 weeks aheadExact sum: 25.2 + 14 + 10.2 + 3.4 = 52.8 · What this means: Earnings are strong; relative strength in its sector is -15.3% and the one-year return is 26.5%. - 11Arhaus, Inc.ARHS · leader · Evidence leans up · 81% evidence52.6out of 100
- 12Barnes & Noble Education, Inc.BNED · turning · Evidence leans up · 67% evidence52.0out of 100
- 13MarineMax, Inc.HZO · leader · Evidence leans down · 64% evidence49.8out of 100
- 14ChargePoint Holdings, Inc.CHPT · breaking out · Evidence leans down · 64% evidence49.1out of 100
- 15Winmark CorporationWINA · basing · Evidence leans down · 85% evidence45.4out of 100
- 16Petco Health and Wellness Company, Inc.WOOF · turning · Evidence leans down · 67% evidence43.7out of 100
- 17Savers Value Village, Inc.SVV · quiet · Too little evidence to rank firmly · 58% evidence43.2out of 100
- 18Build-A-Bear Workshop, Inc.BBW · basing · Evidence leans down · 85% evidence42.7out of 100
- 19EVgo, Inc.EVGO · turning · Evidence leans down · 64% evidence42.1out of 100
- 20National Vision Holdings, Inc.EYE · quiet · Too little evidence to rank firmly · 58% evidence41.2out of 100
- 21Tractor Supply CompanyTSCO · breaking out · Evidence leans down · 85% evidence37.2out of 100
- 22RHRH · basing · Evidence leans down · 85% evidence35.3out of 100
- 23DICK'S Sporting Goods, Inc.DKS · basing · Most evidence points down · 85% evidence31.0out of 100
- 24Arko Corp.ARKO · basing · Most evidence points down · 81% evidence26.9out of 100
- 251-800-FLOWERS.COM, Inc.FLWS · basing · Most evidence points down · 64% evidence26.2out of 100
- 26Bob's Discount Furniture, Inc.BOBS · turning · Too little evidence to rank firmly · 36% evidence61.9out of 100
- 27Olaplex Holdings, Inc.OLPX · Too little evidence to rank firmly · 31% evidence39.9out of 100
- 28Bed Bath & Beyond, Inc. this pageBBBY · Too little evidence to rank firmly · 31% evidence38.8out of 100
How the score adds up
Growth & earnings 20.1/43.75 · Revenue -14.8% · Profit — · Operating margin change 2.7 points · 40% evidenceCapital efficiency 7.9/31.25 · ROCE -9.8% · Operating margin -7.3% · 57% evidenceValuation 10.8/25 · P/E 121.8× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 20.1 + 7.9 + 10.8 = 38.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.
Related companies: Specialty Retail, all 28 compared on one page.
Which companies are close to Bed Bath & Beyond in size?
Bed Bath & Beyond is the 27th largest of 29 Specialty Retail companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Betterware de México, S.A.P.I. de C.V., EVgo, Inc., Barnes & Noble Education, Inc. and Arko Corp. Just below it: Build-A-Bear Workshop, Inc. and ChargePoint Holdings, Inc.
Specialty Retail companies close in size
- Betterware de México, S.A.P.I. de C.V. $675 million
- EVgo, Inc. $569 million
- Barnes & Noble Education, Inc. $458 million
- Arko Corp. $453 million
- Bed Bath & Beyond, Inc. $415 million
- Build-A-Bear Workshop, Inc. $381 million
- ChargePoint Holdings, Inc. $306 million
All 29 Specialty Retail companies, largest first
Companies close in size in other industries
- Chemung Financial Corporation $416 million · Banks - Regional
- Chiron Real Estate Inc. $416 million · REIT - Healthcare Facilities
- Bed Bath & Beyond, Inc. $415 million
- Valhi, Inc. $414 million · Chemicals
- Shoulder Innovations, Inc. $413 million · Medical - Specialties
What else do people ask about Bed Bath & Beyond?
What were Bed Bath & Beyond's latest quarterly results?
Bed Bath & Beyond, Inc. reported revenue of $248 M and a net loss of $16.4 M for the Mar 2026 quarter. Earnings per share were −$0.24. The operating margin was −7.3%, 2.7 percentage points higher than a year earlier (as of 14 August 2026).
What is Bed Bath & Beyond's market cap?
Bed Bath & Beyond, Inc.'s market capitalisation is $415 M at a stock price of $4.35. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 14 August 2026).
How is Bed Bath & Beyond performing?
Bed Bath & Beyond, Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 5 weeks running. This describes what the data did, not a rating (as of 14 August 2026).
Will Bed Bath & Beyond's stock price go up?
This page does not forecast Bed Bath & Beyond, Inc.'s stock price. What it shows instead: the stock price is $4.35. Nobody can reliably say which way a price will move, and this site does not try (as of 14 August 2026).
Does Bed Bath & Beyond have too much debt?
Bed Bath & Beyond, Inc. has a moderate amount of debt: its debt is 0.71× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading.
Keep that borrowing in mind when reading the returns on this page (as of 14 August 2026).
Where is Bed Bath & Beyond in its business cycle?
Bed Bath & Beyond, Inc.'s FY25 operating margin was −5.9%, against a 5-year range of −13.2% to 4.0%: the middle of its own range, neither a peak nor a low. The latest quarter was −7.3%.
Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 14 August 2026).
What could break the Bed Bath & Beyond story?
Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business.
On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 14 August 2026).
Is Bed Bath & Beyond a stock worth studying right now?
What the numbers show: Bed Bath & Beyond, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results.
Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 14 August 2026).
Where do these numbers come from?
Sector Alpha, written by code from the published numbers. Data as of 14 August 2026.
Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.
See the plain-text version of this page.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
US stocks
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.